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Biochemical studies suggest that G-protein-coupled recep-
tors (GPCRs) achieve exquisite signalling speciﬁcity by
forming selective complexes, termed signalosomes. Here,
using cAMP biosensors in single cells, we uncover a pre-
assembled, constitutively active GPCR signalosome, that
couples the relaxin receptor, relaxin family peptide recep-
tor 1 (RXFP1), to cAMP following receptor stimulation
with sub-picomolar concentrations of peptide. The physio-
logical effects of relaxin, a pleiotropic hormone with
therapeutic potential in cancer metastasis and heart
failure, are generally attributed to local production of the
peptide, that occur in response to sub-micromolar concen-
trations. The highly sensitive signalosome identiﬁed here
provides a regulatory mechanism for the extremely low
levels of relaxin that circulate. The signalosome includes
requisite Gas,G bc and adenylyl cyclase 2 (AC2); AC2 is
functionally coupled to RXFP1 through AKAP79 binding
to helix 8 of the receptor; activation of AC2 is tonically
opposed by protein kinase A (PKA)-activated PDE4D3,
scaffolded through a b-arrestin 2 interaction with Ser
704
of the receptor C-terminus. This elaborate, pre-assembled,
ligand-independent GPCR signalosome represents a new
paradigm in GPCR signalling and provides a mechanism
for the distal actions of low circulating levels of relaxin.
The EMBO Journal (2010) 29, 2772–2787. doi:10.1038/
emboj.2010.168; Published online 27 July 2010
Subject Categories: signal transduction
Keywords: AC2; AKAP; cAMP; relaxin; RXFP1
Introduction
cAMP is the prototypical second messenger for signal trans-
duction by G-protein-coupled receptors (GPCRs), which
impacts on virtually every aspect of cellular homeostasis and
physiology. The diverse effects of cAMP require sophisticated
targeting and regulation of intracellular cAMP pools, which is
facilitated by organized entities of adenylyl cyclases (ACs),
phosphodiesterases (PDE), protein kinase A (PKA) and
A-kinase-anchoring proteins (AKAPs; Malbon et al, 2004;
Wong and Scott, 2004; Willoughby and Cooper, 2007; Patel
et al, 2008; Dessauer, 2009). In the case of GPCRs, this
regulation can be further enhanced by the formation of
GPCR signalosomes: macromolecular receptor-linked protein
complexes that facilitate the preferential activation of down-
stream targets. The cAMP output of any such organized
complex, in terms of spatiotemporal complexity or dynamics,
cannot be addressed or observed by traditional cAMP assays,
which examine heterogeneous populations of cells at very low
resolution. Genetically encoded ﬂuorescent-based cAMP sen-
sors are a means for ﬁnely resolving and identifying such sub-
cellular cAMP dynamics in single cells (Nikolaev et al, 2004).
Relaxin is a pleiotropic hormone with wide and varied
physiological effects (Sherwood, 2004; van der Westhuizen
et al, 2008). The peptide is involved in ﬁbrosis, inﬂammation,
wound healing, allergic responses, cancer metastasis and
pregnancy. Consequently, there is considerable interest in
therapeutic applications of relaxin; in particular, its potent
anti-ﬁbrotic effects, and the ability of relaxin to promote the
growth, differentiation and invasiveness of tumour cells
(Klonisch et al, 2007; Du et al, 2010). Furthermore, recent
clinical trials for acute heart failure have shown therapeutic
efﬁcacy for relaxin as a vasodilator (Dschietzig et al, 2009;
Teerlink et al, 2009). The physiological effects of relaxin are
commonly attributed to local production of the hormone in a
wide variety of human tissues; however some major targets—
for example the normal heart, do not appear to synthesize
relaxin (Bathgate et al, 2006; Samuel et al, 2006); so a
function for circulating relaxin is envisaged. The relaxin
that is found in the circulation could be speculated to exert
such effects, but the concentrations are lower than are
effective at any known signalling mechanism for the peptide
(Sherwood, 2004; Gedikli et al, 2009).
The receptors for relaxin were recently de-orphanized (Hsu
et al, 2002); the relaxin family peptide receptor 1 (RXFP1) is a
GPCR, with two binding sites for relaxin: a high-afﬁnity site within
the extracellular-domain leucine-rich repeats, and a low-afﬁnity
site within the transmembrane extracellular loops (Sudo et al,
2003; Bu ¨llesbach and Schwabe, 2005; Halls et al, 2005). A second,
highly homologous receptor, RXFP2, binds insulin/relaxin-like
peptide 3 (INSL3) in addition to relaxin (Kumagai et al, 2002).
The cAMP signalling pathways activated by the stimulation of
RXFP1 with high concentrations of relaxin are well characterized.
The receptor couples to Gas, and negative regulation of cAMP is
exerted by GaoB (Halls et al, 2006); further cAMP accumulation
occurs through Gai3,a c t i v a t i n gaG bg-phosphoinositide 3-kinase
(PI3K)-protein kinase C (PKC) z-AC5 pathway (Nguyen et al,
2003; Nguyen and Dessauer, 2005a,b; Halls et al, 2006, 2009).
Received: 14 May 2010; accepted: 1 July 2010; published online:
27 July 2010
*Corresponding author. Department of Pharmacology, University
of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK.
Tel.: þ44 1223 334063; Fax: þ44 1223 334100;
E-mail: dmfc2@cam.ac.uk
The EMBO Journal (2010) 29, 2772–2787 | & 2010 European Molecular Biology Organization|Some Rights Reserved 0261-4189/10
www.embojournal.org
The EMBO Journal VOL 29 | NO 16 | 2010 &2010 European Molecular Biology Organization
 
EMBO
 
THE
EMBO
JOURNAL
THE
EMBO
JOURNAL
2772In this study, we have tackled the sub-cellular dynamics
of relaxin-mediated cAMP signalling in single cells by using
targeted FRET-based cAMP biosensors: Epac2-camps
(glEpac2), containing the cAMP-binding domain of Epac2
(Nikolaev et al, 2004) and a modiﬁed version of this biosenor
that targets it to the plasma membrane (pmEpac2; Wachten
et al, 2010). This approach revealed a hitherto unsuspected,
constitutively active, sub-picomolar relaxin response media-
ted by an RXFP1-speciﬁc GPCR signalosome. RXFP1 is
pre-coupled to AC2, and this coupling depends on an inter-
action with AKAP79, which is mediated by helix 8 of the
receptor C-terminus. Sub-picomolar relaxin activates AC2
further through Gas and Gbg. This activation is tonically
opposed by the activity of PKA upon a scaffolded PDE4D3,
tethered to RXFP1 through a b-arrestin 2 interaction that
requires Ser
704. This elaborate pre-assembled complex that
affords great sensitivity to relaxin provides a signalling
mechanism for the low circulating levels of this pleiotropic
hormone, which should open the door to a greater under-
standing of the physiological effects of relaxin in target
tissues, such as the normal heart, that do not locally produce
the peptide. A ligand-independent GPCR signalosome, which
is sensitive to attomolar concentrations of ligand, is a novel
paradigm in GPCR signal transduction, and may presage a
new facet of receptor signalling.
Results
Sub-picomolar concentrations of relaxin increase cAMP
The aim of this study was to search for a cAMP response to
low concentrations of relaxin in single cells, using cytosolic
and targeted Epac2-based FRET biosensors (Nikolaev et al,
2004; Wachten et al, 2010). Stimulation of RXFP1 with
increasing concentrations of relaxin revealed a biphasic
cAMP concentration–response curve, with EC50 values of
10.93±0.92aM and 0.35±0.10nM (Figure 1A–D; Table I;
Supplementary Figure S1). The low EC50 demonstrates for
the ﬁrst time a cellular response to sub-picomolar relaxin,
whereas the second EC50 reﬂects previously published values
(Table I; Halls et al, 2005). There was no detectable cAMP
response in cells co-expressing RXFP1 and a sensor that
cannot bind cAMP (pmEpac2 R297E; Figure 1D), or in cells
expressing the pmEpac2 sensor alone (Figure 1A). Note that
stimulation of RXFP1 with a maximal relaxin concentration
(100nM) did not saturate the pmEpac2 sensor, as a combina-
tion of forskolin, 3-isobutyl-1-methylxanthine (IBMX)
and prostaglandin E1 (PGE1) yields higher stimulation
(Figure 1B). Additionally, in cells co-expressing RXFP2 and
pmEpac2, there was no evidence of a cellular response to
sub-picomolar relaxin or INSL3 (Figure 1E and F); thus
sub-picomolar relaxin signalling is unique to RXFP1.
To establish a physiological relevance for signalling by low
concentrations of relaxin, the cAMP response was assessed in
two cell types that endogenously express RXFP1: HeLa cells
(Dschietzig et al, 2004) and primary cultures of rat cardiac
ﬁbroblasts (Samuel et al, 2004). To observe an increase in
cAMP following relaxin stimulation, it was necessary to
‘prime’ endogenous AC with forskolin (1mM). Only the
glEpac2 sensor detected a cAMP response to relaxin in
HeLa cells; sub-picomolar relaxin caused a signiﬁcant
concentration-dependent increase in cAMP, which was main-
tained within the classical relaxin concentration range
(Figure 1G and I). As RXFP1 can couple to Gai/o (Halls
et al, 2006), we assessed the effect of the Gai/o inhibitor
pertussis toxin (PTX); this revealed the biphasic concentra-
tion–response curve initially observed in HEK293 cells (EC50:
7.10±0.94aM; 0.18±0.09nM; Table I), and indicates that
the classical relaxin response in HeLa cells involves the
inhibition of AC through Gai/o.
In cardiovascular disease models, activation of endogen-
ous RXFP1 in cardiac ﬁbroblasts by relaxin results in im-
portant cardioprotective effects, including inhibition of
hypertrophy and ﬁbrosis (Du et al, 2010); thus this is an
important model in which to study relaxin-stimulated signal-
ling. Rat cardiac ﬁbroblasts are poorly transfected, so it was
necessary to infect the cells with an adenoviral version of the
cytosolic Epac1-camps sensor (Ad-glEpac1; Nikolaev et al,
2005; Figure 1H and I). Sub-picomolar concentrations of
relaxin induced a signiﬁcant increase in cAMP, which then
declined within the classical concentration range. The latter
phase is consistent with cell population assays, which
describe an inhibitory cAMP response curve (Halls ML,
unpublished data). Pre-treatment of ﬁbroblasts with PTX
also revealed a biphasic, stimulatory concentration–response
curve (EC50: 5.11±1.10aM; 0.30±0.08nM; Table I).
Sub-picomolar relaxin signalling: Gas and Gbc activate
AC2
To determine the mechanism whereby sub-picomolar
concentrations of relaxin activate cAMP, we inhibited
G-protein modulators of the classical relaxin response:
Gas,G ai/o and Gbg (Figure 2; Halls et al, 2006). Inhibition
of Gai/o using PTX did not affect the cAMP response to
sub-picomolar concentrations of relaxin; however, the max-
imal cAMP response to relaxin was enhanced (Figure 2A and
B). Thus, the Gai3-Gbg-PI3K-PKCz pathway does not generate
the cAMP detected by the pmEpac2 sensor. In contrast,
inhibition of Gas by NF449 (Hohenegger et al, 1998) signiﬁ-
cantly inhibited the 10fM relaxin response (Figure 2C and D).
To conﬁrm this ﬁnding, Gas was primed using a low
concentration of cholera toxin (200ng/ml). This treatment
potentiated basal and relaxin-stimulated cAMPaccumulation,
with the response to 10fM relaxin reaching the maximal
relaxin response (Figure 2C and D). To examine any involve-
ment of Gbg subunits, the inhibitors gallein (Lehmann et al,
2008) and mSIRK (Scott et al, 2001; Goubaeva et al, 2003)
were used (Figure 2E and F); both completely abolished the
cAMP accumulation stimulated by 10fM relaxin. Thus, in-
creased cAMP elicited by sub-picomolar concentrations of
relaxin requires both Gas and Gbg.
Increased cAMP can occur by either activation of AC or
inhibition of PDE. An AC inhibitor, 20,50-dd-30-AMP-
bis(tBuSATE) (ddAB; Laux et al, 2004), completely abolished
the response to 10fM relaxin (Figure 3A and B). Of the nine
membrane-bound AC isoforms, only three are activated by
both Gas and Gbg: AC2, AC4 and AC7; of these, only AC2 and
AC7 are expressed in HEK293 cells (Hellevuo et al, 1993;
Figure 3C and D). Overexpression of AC2 signiﬁcantly in-
creased cAMP accumulation under all conditions. The en-
hanced basal cAMP observed following AC2 overexpression
depended upon co-expression of RXFP1: in the absence of the
receptor, overexpression of AC2 had no effect upon basal
cAMP (Figure 3E and F). In contrast, overexpression of AC7
abolished the cAMP elicited by 10fM relaxin; overexpression
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causing inhibition of the cAMP response. Nevertheless, this
result demonstrates an absolute requirement for AC2 in sub-
picomolar relaxin signalling.
Activation of AC2 requires an AKAP
Two immediate possibilities are suggested for the sustained
cAMP stimulated by sub-picomolar concentrations of
relaxin: (1) that this pool of cAMP is tightly controlled by a
PDE and (2) that AC2 is tonically inhibited by an AKAP
(Piggott et al, 2008; Efendiev et al, 2010). We ﬁrst investigated
AKAP involvement by utilizing an inhibitor of AKAP/PKA
interactions, St-Ht31 (Hundsrucker et al, 2006; Figure 3G
and H). St-Ht31 completely abolished the cAMPaccumulation
stimulated by 10fM relaxin, and there was no effect
of the negative control, St-Ht31-P. Thus, an AKAP is
required for the increase in AC2 activity following RXFP1
stimulation.
Figure 1 A sub-picomolar relaxin response. cAMP biosensors in single cells revealed a response to sub-picomolar concentrations of relaxin
(n¼10–74). (A) Stimulation of HEK293 cells expressing pmEpac2 or co-expressing pmEpac2 and RXFP1 with a sub-maximal concentration of
relaxin (1nM) over 5min. (B) HEK293 cells co-expressing RXFP1 and pmEpac2 were stimulated with vehicle (0.001% triﬂuoroacetic acid,
TFA), or a low (1pM), sub-maximal (1nM) or high (100nM) concentration of relaxin over 5min. All cells were stimulated at 0min, a maximal
cAMP response (FIP; 10mM forskolin, 100mM IBMX, 100nM PGE1) was induced at 6min. Note that saturation of the probes is not achieved
with relaxin stimulation, as FIP gives a greater response. (C) HEK293 cells expressing pmEpac2. (D) Relaxin (10aM–100mM) stimulation of
RXFP1 co-expressed with pmEpac2 or pmEpac2 R297E (a sensor that cannot bind cAMP) in HEK293 cells. (E) Relaxin (1pM–1mM) or INSL3
(100aM–100mM) stimulation of RXFP2 co-expressed with pmEpac2 in HEK293 cells. (F) HEK293 cells expressing pmEpac2. (G) Relaxin
(10aM–100mM) stimulation of HeLa cells (endogenously express RXFP1) transfected with glEpac2, in the presence of forskolin (1mM) and the
Gai/o inhibitor pertussis toxin (PTX; 100ng/ml, 16h). (H) Relaxin (10aM–100mM) stimulation of primary rat cardiac ﬁbroblasts (endogenously
express RXFP1) infected with Ad-glEpac1, in the presence of forskolin (1mM) and PTX. (I) HeLa cells (top) and rat cardiac ﬁbroblasts (bottom)
expressing glEpac2 or Ad-glEpac1, respectively. Data are expressed as the 5 or 12min area under the curve (AUC). Symbols represent means,
error bars, s.e.m. *Po0.05, **Po0.01 and ***Po0.001 relaxin versus basal;
^Po0.05,
^^Po0.01 and
^^^Po0.001 INSL3 or relaxin with PTX
versus basal; two-way ANOVA with Bonferroni post tests.
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sub-picomolar relaxin signalling
As cAMP can only be degraded by PDE activity, we examined
the effect of a PDE inhibitor, IBMX, upon the concentration–
response to relaxin (Supplementary Figure S2). Inhibition of
PDE activity abolished the biphasic concentration–response
curve, by increasing basal cAMP levels such that no further
increases were observed at sub-picomolar relaxin concentra-
tions. We then compared the effect of IBMX upon basal cAMP
levels in HEK293 cells transiently expressing RXFP1, RXFP2 or
empty vector, pcDNA (Figure 4A and B). IBMX signiﬁcantly
increased basal cAMP only in cells expressing RXFP1. Thus,
there is a constitutive negative regulation of cAMP accumula-
tion in HEK293 cells that is induced by RXFP1 expression.
To identify the PDE isoform that negatively regulates the
cAMP accumulation stimulated by sub-picomolar relaxin, we
used PDE3- and PDE4-selective inhibitors; PDE3 and PDE4
are the main isoforms expressed in HEK293 cells (Lynch et al,
2005; Figure 4C and D; Supplementary Figure S2). Both IBMX
and the PDE4-speciﬁc Ro 20-1724 signiﬁcantly increased
basal cAMP, and there was no further increase following
stimulation with 10fM relaxin. In contrast, there was no
signiﬁcant effect of the PDE3 inhibitor, cilostamide, upon
basal, and cAMP accumulation remained responsive to sti-
mulation with 10fM relaxin. Thus, PDE4 regulates the cAMP
generated following AC2 stimulation by RXFP1. Further,
vacant receptors exert a low level of constitutive cAMP
signalling, which is tightly controlled by PDE4 activity;
Table I Comparison of EC50 values for cAMP generation by relaxin and INSL3 using different methodologies
Cell type Sensor Relaxin INSL3
EC50 1 (aM) EC50 2 (nM) EC50 (nM)
HEK293-expressing RXFP1 a-Screen assay
a Undetectable 0.47±0.21 NA
glEpac2 140.34±20.73 0.62±0.12 NA
pmEpac2 10.93±0.92 0.35±0.10 NA
HeLa glEpac2 7.10±0.94 0.18±0.09 NA
Cardiac ﬁbroblasts Ad-glEpac1 5.11±1.10 0.30±0.08 NA
HEK293-expressing RXFP2 glEpac2 NA 57.70±6.94 7.74±1.67
pmEpac2 NA 18.09±3.84 1.42±0.92
HEK293-expressing RXFP1/2 pmEpac2 NA 1.05±0.21 NA
HEK293-expressing RXFP2/1 pmEpac2 7.86±1.30 0.33±0.08 0.26±0.04
The average EC50 values for cAMP accumulation in response to relaxin or INSL3 stimulation of RXFP1 are shown. NA indicates that the ligand
does not activate the response described by the EC50 value.
aEC50 values were obtained from Halls et al (2005), using a Perkin Elmer a-screen cAMP kit (measuring cAMP accumulation in cell
populations).
Figure 2 A sub-picomolar relaxin response requires Gas and Gbg. Sub-picomolar relaxin signalling was examined at the G-protein level in
HEK293 cells co-expressing RXFP1 and pmEpac2, and stimulated with vehicle (0.001% TFA), 10fM or 10nM relaxin (n¼43–51). (A) Cells were
pre-incubated with the Gai/o inhibitor PTX (100ng/ml, 16h) and stimulated with 10fM relaxin. (B) The 5min area under the curve (AUC) from
(A) for TFA, 10fM and 10nM relaxin. (C) Cells were pre-incubated with the Gas-speciﬁc antagonist NF449 (10mM, 30min), or the Gas-activator
cholera toxin (200ng/ml, 90min) and stimulated with 10fM relaxin. (D) The 5min AUC from (C) for TFA, 10fM and 10nM relaxin. (E)G bg
subunits were inhibited by gallein (10mM, 30min) or mSIRK (5mM, 15min) and stimulated with 10fM relaxin. (F) The 5min AUC from (E) for
TFA, 10fM and 10nM relaxin. Data are expressed relative to the maximal cAMP response (FIP; 10mM forskolin, 100mM IBMX, 100nM PGE1), or
as the 5min AUC. Bars represent means, error bars s.e.m. ***Po0.001 versus own basal;
^Po0.05,
^^Po0.01 and
^^^Po0.001 versus response
to relaxin alone; two-way ANOVA with Bonferroni post tests.
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relaxin drives further cAMP production by AC2, overcoming
the tonic regulation exerted by PDE4.
Activation of the long isoforms of PDE4 (PDE4D3
and PDE4D5) occurs by PKA-mediated phosphorylation
(MacKenzie et al, 2002), thus we tested the effect of two
PKA inhibitors, H89 and KT5720 (Figure 4E and F). Inhibition
of PKA had the same effect as inhibition of PDE4: basal cAMP
levels were signiﬁcantly increased, and stimulation with
10fM relaxin caused no further increase in cAMP. There
was no additive effect if both PKA and PDE4 were simulta-
neously inhibited (Supplementary Figure S2), which suggests
that PKA is upstream of PDE4. Therefore, activation of the
PDE4-mediated negative regulation of cAMP depends
on PKA.
b-Arrestin-mediated scaffolding of PDE often accompanies
GPCR activation, and is an important mechanism whereby
GPCRs are both desensitized and internalized. Thus, we
assessed the effect of knockdown of b-arrestin 1 or b-arrestin
2 using siRNA (Figure 4G and H), which resulted in a
signiﬁcant reduction of b-arrestin protein (Figure 4I).
Expression of b-arrestin 2 siRNA, but not b-arrestin 1 or
scrambled siRNA, signiﬁcantly increased basal cAMP accu-
mulation, and there was no further increase in cAMP induced
by 10fM relaxin. There was also no effect of siRNA upon the
classical cAMP response to relaxin, which agreed with
previous reports (Callander et al, 2009).
Negative regulation by b-arrestin 2 and PDE4 requires
Ser
704 of RXFP1
We wished to determine whether the Gas-mediated stimula-
tion of cAMP elicited by different concentrations of relaxin
acting on RXFP1 could be separated by manipulation of
receptor structure—that is could we preserve one set of
effects while eliminating the other (Figure 5). Application
of receptor chimeras developed earlier (Sudo et al, 2003;
Halls et al, 2005) revealed the necessity of the RXFP1-
transmembrane/C-terminus for sub-picomolar signalling,
Figure 3 A cellular response to sub-picomolar relaxin requires AC2 and an AKAP. Sub-picomolar relaxin signalling was examined downstream
of Gas and Gbg, in HEK293 co-expressing RXFP1 and pmEpac2, and stimulated with vehicle (0.001% TFA), 10fM or 10nM relaxin (n¼11–52).
(A) AC activity was inhibited by 20,5 0-dd0-30-AMP-bis(t-BuSATE) (ddAB; 1mM, 30min) and cells were stimulated with 10fM relaxin. (B) The
5min area under the curve (AUC) from (A) for TFA, 10fM and 10nM relaxin. (C) The effect of overexpression of AC2 or AC7 on the response to
10fM relaxin. (D) The 5min AUC from (C) for TFA, 10fM and 10nM relaxin. (E) The effect of AC2 overexpression with and without co-
expression of RXFP1 upon basal cAMP. (F) The 5min AUC from (E) for TFA, 10fM and 10nM relaxin. (G) AKAP/PKA binding was inhibited
using St-Ht31 or control peptide St-Ht31-P (both 20mM, 45min) and cells were stimulated with 10fM relaxin. (H) The 5min AUC from (G) for
TFA, 10fM and 10nM relaxin. Data are expressed relative to the maximal cAMP response (FIP; 10mM forskolin, 100mM IBMX, 100nM PGE1), or
as the 5min AUC. Bars represent means, error bars s.e.m. *Po0.05 and ***Po0.001 versus basal;
^Po0.05,
^^Po0.01 and
^^^Po0.001 versus
relaxin/RXFP1; two-way ANOVA with Bonferroni post tests.
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Thus, a biphasic response was evident upon expression of
RXFP2/1 (RXFP2-ectodomain, RXFP1-transmembrane/C-ter-
minus), but not RXFP1/2 (RXFP1-ectodomain, RXFP2-trans-
membrane/C-terminus; Figure 5A and B; Table I).
Furthermore, only relaxin, but not the closely related peptide
INSL3, increased cAMP accumulation at sub-picomolar con-
centrations. Thus, the biphasic concentration–response is not
only speciﬁc for RXFP1, but also for relaxin.
The involvement of the RXFP1 C-terminus was then ex-
plored further using a number of previously described recep-
tor mutants (Halls et al, 2009). The glEpac2 sensor was used
for these experiments because of very low cAMP levels
detected by the pmEpac2 sensor following activation of
some of the mutants. Truncation of the receptor C-terminus
beyond helix 8 (tRXFP1-703; Figure 5C and D) removed the
negative regulation of cAMP signalling. In contrast to the
effects of PDE4 or PKA inhibition, or b-arrestin 2 knockdown,
tRXFP1-703 remained responsive to stimulation with sub-
picomolar concentrations of relaxin. Thus, truncation of the
RXFP1 C-terminus eliminates the regulation of sub-picomolar
signalling but not Gs-mediated activation of AC2. The max-
imal cAMP response to relaxin was also reduced following
truncation, because of loss of activation of the Gai3 pathway
(Halls et al, 2009).
Overlapping the end of helix 8 and the ﬁrst few residues of
the C-terminus is a putative phosphorylation motif (residues
700–708; RQRKSMDSK), which if basally phosphorylated
could potentially provide an interaction site for b-arrestin 2.
Mutation of the target serine to alanine (RXFP1 S704A; Figure
5C and D) had the same effect as inhibition of PKA and PDE4,
and knockdown of b-arrestin 2: basal cAMP accumulation
was signiﬁcantly increased. Furthermore, there was no addi-
tional effect of PKA inhibition in response to relaxin stimula-
tion of RXFP1 S704A (Supplementary Figure S3). Thus,
regulation by b-arrestin 2, PKA and PDE4 requires Ser
704,
Figure 4 Negative regulation of sub-picomolar relaxin signalling requires PKA, PDE4 and b-arrestin 2. Negative regulation was examined in
HEK293 co-expressing RXFP1 or RXFP2, and pmEpac2, and stimulated with vehicle (0.001% TFA), 10fM or 10nM relaxin (n¼44–51). (A) The
effect of PDE inhibition (IBMX, 100mM, 30min) on basal cAMP in cells expressing RXFP1 or RXFP2. (B) The 5min area under the curve (AUC)
from (A) for TFA, 10fM and 10nM relaxin. (C) The effect of IBMX (general inhibitor), Ro 20-1724 (PDE4 speciﬁc; 10mM, 30min) or cilostamide
(PDE3 speciﬁc; 10mM, 30min) on the basal cAMP. (D) The 5min AUC from (C) for TFA, 10fM and 10nM relaxin. (E) PKAwas inhibited by H89
(10mM, 30min) or KT5720 (1mM, 30min) and the basal cAMP measured. (F) The 5min AUC from (E) for TFA, 10fM and 10nM relaxin.
(G) The effect of b-arrestin 1, b-arrestin 2 or scrambled siRNA (all 100nM) on the basal cAMP response. (H) The 5min AUC from (G) for TFA,
10fM and 10nM relaxin. (I) Western blots showing speciﬁc knockdown of b-arrestin 1 or b-arrestin 2 by targeted siRNA compared with
controls. Blots were re-probed with tubulin to ensure equal protein loading (Supplementary data). Data are expressed relative to the maximal
cAMP response (FIP; 10mM forskolin, 100mM IBMX, 100nM PGE1), or as the 5min AUC. Bars represent means, error bars s.e.m. *Po0.05,
**Po0.01 and ***Po0.001 versus basal;
^^Po0.01 and
^^^Po0.001 versus relaxin/pcDNA; two-way ANOVA with Bonferroni post tests.
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the receptor C-terminus beyond helix 8.
To exclude a function for the remainder of the C-terminus,
we examined two additional mutant receptors (Figure 5E and
F): a receptor lacking the ﬁnal 10 amino acids of the C-
terminus (tRXFP1-747) and another phosphorylation mutant
within a potential site encompassing the ﬁnal 10 residues
(residues 748–757; SQSTRLNSYS; RXFP1 S755A). There was
no effect of either of these receptor mutations upon the cAMP
response to sub-picomolar concentrations of relaxin. The
maximal cAMP response to relaxin was reduced through
tRXFP1-747, because of loss of activation of the Gai3 pathway
as previously reported (Halls et al, 2009). On the basis of this
series of studies, we would conclude that there are speciﬁc
properties within the molecular nature of RXFP1 that are
necessary for regulation of the high-afﬁnity response. In later
experiments, we would exploit these apparent characteristics
in order to determine whether a different cadre of molecular
components would continue to associate with appropriately
modiﬁed receptor elements.
Figure 5 Sub-picomolar relaxin signalling requires the RXFP1-transmembrane/C-terminus, negative regulation requires Ser
704. The region of
RXFP1 controlling sub-picomolar relaxin signalling was examined using mutant receptors in HEK293 cells expressing pmEpac2 or glEpac2
(n¼10–45). (A) Relaxin (10aM–100mM) or INSL3 (100mM) stimulation of RXFP1/2 (RXFP1-ectodomain, RXFP2-transmembrane/C-terminus)
co-expressed with pmEpac2. (B) Relaxin or INSL3 (10aM–100mM) stimulation of RXFP2/1 (RXFP2-ectodomain, RXFP1-transmembrane/
C-terminus) co-expressed with pmEpac2. (C) The basal cAMP response in cells co-expressing RXFP1, tRXFP1-703 (truncated following helix 8;
left) or RXFP1 S704A (potential phosphorylation site mutation; right) and glEpac2. (D) The 5min area under the curve (AUC) from (C) for TFA,
10fM and 10nM relaxin. (E) The basal cAMP response in cells co-expressing RXFP1, tRXFP1-747 (truncation of ﬁnal 10 residues; left) or RXFP1
S755A (potential phosphorylation site mutation; right) and glEpac2. (F) The 5min AUC from (E) for TFA, 10fM and 10nM relaxin. Data are
expressed relative to maximal cAMP (FIP; 10mM forskolin, 100mM IBMX, 100nM PGE1), or as the 5min area AUC. Bars represent means, error
bars s.e.m. *Po0.05, **Po0.01 and ***Po0.001 relaxin versus basal;
^^Po0.01 and
^^^Po0.001 INSL3/mutant versus basal/RXFP1
respectively; two-way ANOVA, Bonferroni post tests.
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whereas b-arrestin 2, PDE4D3 and PKA associate with
helix 8 and residues 704–725
The molecular components of the RXFP1 signalosome, and
their sites of interaction with the C-terminus, were then
directly examined using GST pull-down assays (Figure 6)
and co-immunoprecipitation (co-IP) (Figure 7).
We generated GST fragments of the RXFP1 C-terminus
(Figure 6A), and assessed pull down of candidate proteins
from HEK293 cell lysate by immunoblotting. b-Arrestin 2 was
pulled down by helix 8 and residues 704–725 (Figure 6B and
D). As our HEK293 cells principally express PDE4D5,
PDE4D3 and PDE4B2 (Willoughby et al, 2007), and only
the long isoforms of PDE4 (PDE4D3 and PDE4D5) are acti-
vated by PKA phosphorylation (MacKenzie et al, 2002),
immunoreactivities from pull-down experiments were exam-
ined with a PDE4D-speciﬁc antibody (Figure 6B and D). Two
bands were evident in the input, corresponding to the antici-
pated molecular weights of PDE4D5 (105kDa; MacKenzie
et al, 2002) and PDE4D3 (95kDa; Terrenoire et al, 2009).
As b-arrestin 2 can sequester PDE4 to GPCRs (Perry et al,
2002), we anticipated that the relevant PDE4 isoform would
be pulled down by the same fragments of the RXFP1 C-
terminus as b-arrestin 2: helix 8 and residues 704–725.
Only one band was pulled down by the RXFP1 C-terminus,
corresponding to the molecular weight of PDE4D3. This
Figure 6 The RXFP1 signalosome: AC2, AKAP79, b-arrestin 2, PKA and PDE4D3. Potential interactions between RXFP1 and mediators of the
sub-picomolar relaxin response were assessed by GST pull down from HEK293 lysate using fragments of the RXFP1 C-terminus (n¼4), and
conﬁrmed in single-cell FRET studies. (A) Fragments of the RXFP1 C-terminus were tagged with GST. (B) Representative blots of GST pull-
down assays probed with b-arrestin 2, PDE4D and PKAa-catalytic subunit antibodies (Supplementary data). (C) Representative blots probed
with AKAP79, AKAP149 and gravin antibodies (Supplementary data). (D) Densitometry was calculated for b-arrestin 2, PDE4D3 and PKA.
(E) Densitometry was calculated for AKAP79. Data are expressed as band density relative to pull down by GSTalone. Bars represent means,
error bars s.e.m. *Po0.05 and **Po0.01 versus GSTalone, two-way ANOVA with Bonferroni post tests. (F) Dominant negative PDE4D3 and
PDE4D5 were overexpressed in HEK293 cells with RXFP1 and pmEpac2 for single-cell FRETstudies. The 5min area under the curve (AUC) was
calculated for TFA, 10fM and 10nM relaxin (n¼16–43). Western blotting shows expression of the two isoforms with equal loading conﬁrmed
using a tubulin antibody (Supplementary data). (G) The effects of AKAP79 shRNA or pSilencer control were assessed in HEK293 cells co-
expressing RXFP1 and pmEpac2 using single-cell FRET studies. The 5min AUC was calculated for TFA, 10fM and 10nM relaxin (n¼20–51).
Western blotting shows decreased AKAP79 protein following shRNA transfection with equal protein loading conﬁrmed using a tubulin
antibody (Supplementary data). Bars represent means, error bars s.e.m. *Po0.05 and ***Po0.001 versus own basal;
^Po0.05 and
^^Po0.01
versus control; two-way ANOVA with Bonferroni post tests.
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cAMP stimulated by sub-picomolar relaxin. Immunoblotting
with an antibody targeting the PKAa-catalytic domain also
revealed an interaction with helix 8 and residues 704–725
(the antibody identiﬁes two bands; Figure 6B and D).
To conﬁrm the speciﬁc involvement of PDE4D3 over
PDE4D5, we overexpressed dominant negative mutants
(which retain b-arrestin binding, but lack catalytic activity;
Baillie et al, 2003; McCahill et al, 2005) of the two isoforms
and examined the RXFP1-stimulated cAMP response using
the pmEpac2 sensor (Figure 6F). Overexpression of dominant
negative PDE4D3 signiﬁcantly increased basal cAMP, but
there was no further increase in the cAMP response to
10fM relaxin. Conversely, overexpression of dominant nega-
tive PDE4D5 signiﬁcantly increased the cAMP response to all
concentrations of relaxin, suggesting a global effect of
PDE4D5, but a targeted action of PDE4D3 on the sub-
picomolar relaxin response.
As HEK293 cells express three major AKAPs (AKAP79,
AKAP149 and gravin; Gardner et al, 2006; Willoughby et al,
2006), we also probed GST pull-down blots with speciﬁc
AKAP antibodies. There was no pull down of AKAP149 or
gravin by RXFP1 (Figure 6C). AKAP79 was only pulled down
by helix 8 (Figure 6C and E). To conﬁrm a speciﬁc involve-
ment of AKAP79 in the RXFP1 signalosome, we assessed the
effect of AKAP79 knockdown upon the cAMP response
detected by the pmEpac2 sensor (Figure 6G). Knockdown
of AKAP79 using shRNA results in a signiﬁcant reduction of
AKAP79 protein (Figure 6G), and abolished the cAMP
response to 10fM relaxin.
Figure 7 AKAP79 and AC2 associate with full-length RXFP1, and the interaction of RXFP1 with b-arrestin 2, PDE4D3 and PKA depends upon
Ser
704. The proteins that constitute the RXFP1 signalosome were assessed for interactions with the full-length receptor and RXFP1 S704A by
immunoprecipitation (IP) of AC2-HA or dominant negative PDE4D3 (n¼3–4). (A) Representative blots of AC2-HA or dominant negative (DN)
PDE4D3 IP from HEK293 lysate expressing pcDNA and AC2-HA, FLAG-RXFP1 and AC2-HA, or FLAG-RXFP1 S704A and AC2-HA, and probed
with FLAG, AKAP79, HA, b-arrestin 2, PDE4D or PKAa-catalytic subunit antibodies (Supplementary data). (B) Average densitometry for AC2-
HA IP. (C) Average densitometry for PDE4D3 DN IP. Data are expressed as band density relative to 5% input. Bars represent means, error bars
s.e.m. *Po0.05, **Po0.01 and ***Po0.001 versus pcDNA;
^Po0.05,
^^Po0.01 and
^^^Po0.001 versus RXFP1 S704A; one-way ANOVA with
Newman–Keuls multiple comparison test.
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also interacted with full-length RXFP1, we performed two
different co-IP experiments: one looking for proteins that co-
IP with overexpressed AC2-HA, and a second to identify
proteins that co-IP with overexpressed dominant negative
PDE4D3 (Figure 7). Results showed co-IP of RXFP1 with AC2-
HA, which was unaffected by mutation of Ser
704 (RXFP1
S704A; Figure 7A and B). AKAP79 associated with AC2-HA
in the absence and presence of RXFP1, and this was also
unaffected by the S704A mutation (Figure 7A and B).
Conversely, b-arrestin 2, PDE4D3 and PKA all exhibited
signiﬁcantly increased co-IP with AC2-HA in the presence
of RXFP1, which did not occur in lysate from cells expressing
RXFP1 S704A (Figure 7A and B). Thus, AKAP79 and AC2-HA
associate with full-length RXFP1, and the association of
b-arrestin 2, PDE4D3 and PKA depends upon Ser
704. The
absolute requirement of Ser
704 was further established using
co-IP of overexpressed dominant negative PDE4D3: while
RXFP1, AKAP79, AC2-HA, b-arrestin 2 and PKA all associated
with PDE4D3, these interactions were abolished if Ser
704 was
mutated (Figure 7A and C). Note that there are some
expected constitutive associations, for example between
AC2 and AKAP79 (Efendiev et al, 2010), but there is a clear
and speciﬁc increment in these (and other) associations upon
RXFP1 expression in both biochemical and functional terms
(Figures 4 and 6), conﬁrming the targeted formation of an
RXFP1-speciﬁc complex.
AC2 interacts with RXFP1 through AKAP79, whereas
the association with PDE4D3 and PKA depends upon
b-arrestin 2 binding to Ser
704
The contact points between the proteins of the RXFP1 signa-
losome were examined by assessing the effect of knockdown
of either AKAP79 or b-arrestin 2 upon GST pull-down assays
(Figure 8) or co-IP studies (Figure 9).
Knockdown of b-arrestin 2 signiﬁcantly decreased the pull
down of b-arrestin 2, PDE4D3 and PKA by helix 8 and
residues 704–725 (Figure 8A and B). There was no effect of
knockdown on the non-speciﬁc pull down of these proteins
by GST alone or residues 726–747. Thus, b-arrestin 2 is
required for the interaction of both PDE4D3 and PKA with
the RXFP1 C-terminus. Although a recent proteomics study
conﬁrmed a PDE4D3/b-arrestin 2 interaction, it failed to
detect an association between overexpressed FLAG-tagged
b-arrestin 2 and PKA (Xiao et al, 2007). However, that
study also failed to ﬁnd expected interactions between the
overexpressed b-arrestins and any GPCRs (despite overex-
pression of the angiotensin 1A receptor). Thus, although
potentially highly sensitive, proteomics approaches may
still be susceptible to confounding factors such as detergent
choice and the use of protein tags.
There was no effect of b-arrestin 2 knockdown on the
pull down of AKAP79 by helix 8 (Figure 8A and C), conﬁrm-
ing that the interaction between AKAP79 and RXFP1 is
independent of b-arrestin 2. Similarly, knockdown of b-arrest-
in 2 did not signiﬁcantly affect the association between
AC2-HA and full-length RXFP1 or AKAP79 (Figure 9A and
B). However, the interactions between AC2-HA and b-arrestin
2, PDE4D3 and PKA were signiﬁcantly decreased (Figure 9A
and B). Furthermore, knockdown of b-arrestin 2 signiﬁcantly
reduced the co-IP between PDE4D3 and all proteins
within the RXFP1 signalosome (Figure 9A and C), thus the
interaction of these proteins with PDE4D3 depends on
b-arrestin 2.
Knockdown of AKAP79 signiﬁcantly decreased the co-IP
between AC2-HA and all proteins within the RXFP1 signalo-
some (Figure 9A and B), which conﬁrms that AKAP79
scaffolds AC2 to RXFP1. Conversely, knockdown of AKAP79
did not affect the association between PDE4D3 and b-arrestin
2, PKA or RXFP1, but signiﬁcantly reduced the interaction
between PDE4D3 and both AKAP79 and AC2-HA (Figure 9A
and C).
Thus, the stimulatory (AC2 and AKAP79) and regulatory
(b-arrestin 2, PDE4D3 and PKA) components of the RXFP1
signalosome interact with the receptor independently; AC2
associates with RXFP1 through AKAP79, and b-arrestin 2
binding to Ser
704 recruits PDE4D3 and PKA to the protein
complex (Figure 10).
Discussion
Although a wide range of tissues locally produce high con-
centrations of relaxin that are effective at the traditional
relaxin signalling pathways, the peptide only occurs at low
concentrations in the circulation (Gedikli et al, 2009). To date,
there has been no evidence of a physiological function for
such low concentrations of circulating relaxin (Sherwood,
2004). The effects presented here of sub-picomolar relaxin
upon a constitutively active RXFP1 provide, for the ﬁrst time,
a cellular response to low levels of the circulating hormone.
This response was detectable in a wide range of cell types,
and thus provides a mechanism whereby circulating levels of
relaxin could affect physiological targets where there is
minimal production of the hormone, such as the normal
heart. Such sensitivity has been demonstrated in a few
other physiological systems (Ying et al, 1986; Alleva et al,
1997; Ueda et al, 2001), but is unheard of for a GPCR and thus
represents a novel paradigm for GPCR signalling.
The response that we have uncovered here is completely
different from known RXFP1 signalling. The classical cAMP
response generated by relaxin activation of RXFP1 is well
characterized (Nguyen et al, 2003; Nguyen and Dessauer,
2005a,b; Halls et al, 2006, 2009), but of these components
only Gas and Gbg are involved in sub-picomolar relaxin
signalling (Supplementary Figure S2). Furthermore, neither
AKAP79 nor b-arrestin 2 are involved in the classical relaxin
response, as demonstrated here by a lack of effect of inhibi-
tors upon the cAMP production stimulated by 10nM relaxin.
Even more signiﬁcantly, stimulation of RXFP1 with 10nM
(but not 10fM) relaxin reduces the association between
RXFP1 and PDE4D3 or AC2 (Supplementary Figure S4),
suggesting dissociation of the RXFP1 signalosome following
activation of the classical relaxin response. Thus, a pathway
that is completely independent of the classical cAMP re-
sponse mediates the increase in cAMP stimulated by sub-
picomolar concentrations of relaxin.
An unusual characteristic of the classical RXFP1 regulatory
repertoire is the lack of signiﬁcant receptor desensitization
and internalization (Callander et al, 2009; Kern and Bryant-
Greenwood, 2009). This is in contrast to more prototypical
GPCRs, such as the b2-adrenoceptor, and may potentially
explain the toleration of constitutive activity documented
here, in addition to the speciﬁcity of the RXFP1 complex for
PDE4D3, over the preference of a b2-adrenoceptor/AKAP79/
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Lynch et al, 2005; Willoughby et al, 2007). The lack of
appreciable receptor desensitization and internalization
may also rationalize another unique feature of this signalo-
some that opposes the accepted behavioural paradigm for
GPCRs: the constitutive dual coupling of RXFP1 to both
G-proteins and b-arrestin 2. These same characteristics have
recently been demonstrated by the D4 dopamine receptor
(Rondou et al, 2010; Spooren et al, 2010), and thus may
represent an emerging and particular hallmark of receptors
that constitutively associate with b-arrestins, but do not
desensitize or internalize. However, an apparent contradic-
tion is seen between the present results and those of
Callander et al (2009) who reported cytosolic expression of
GFP-tagged b-arrestin 2 in cells expressing RXFP1. This
difference might reﬂect the high expression of GFP-b-arrestin
2 in that study, but is more likely due to the pre-formation of
the complex that we are describing with endogenous b-
arrestin 2 (precluding association with GFP-b-arrestin 2), or
the possibility that RXFP1 cannot physically associate with
GFP-b-arrestin 2.
Detailed examination of sub-picomolar relaxin signalling
also revealed a novel constitutive activity of RXFP1. Only in
cells expressing RXFP1, but not RXFP2, did inhibition of PDE
signiﬁcantly increase basal cAMP. Furthermore, overexpres-
sion of AC2 only increased basal cAMP upon co-expression of
RXFP1. Thus at rest, a constitutive stimulation of AC2 by
RXFP1 increases cAMP accumulation, which is tonically
opposed by PDE4D3. Additional regulation of the activity of
the RXFP1 signalosome may also be exerted by AKAP79,
which can interact with AC2, AC3, AC5, AC6, AC8 and AC9.
Although the interaction of AKAP79 with AC3 and AC9 is
neutral, the same association causes inhibition of AC2, AC5,
AC6 and AC8 activity (Bauman et al, 2006; Efendiev et al,
2010; Willoughby et al, 2010). Thus, inhibition of AC2 by
AKAP79 may provide an additional means of dampening the
Gas and Gbg-mediated activation, explaining the inability of
10fM relaxin to elevate cAMP levels beyond those seen with
PDE4 inhibition.
We have comprehensively dissected both the molecular
and functional composition of the sub-picomolar relaxin
response: stimulation of the receptor leads to Gas- and Gbg-
dependent activation of AC2, which depends on the interac-
tion of AKAP79 with helix 8 of the receptor C-terminus
(Figure 10). AKAP79 scaffolding of AC2 to RXFP1 likely
facilitates efﬁcient transduction of the cAMP signal.
Negative regulation of the sub-picomolar relaxin response
occurs through PKA activation of PDE4D3, both of which are
tethered to the receptor by b-arrestin 2. Binding of this
negative regulatory complex requires Ser
704, and thus the
Figure 8 The pull down of PDE4D3 and PKA depends on b-arrestin 2. To assess the protein–protein interactions within the RXFP1
signalosome, the effect of knockdown of b-arrestin 2 upon the GST pull-down assay was assessed (n¼4). (A) Representative blots of GST
pull-down assays from HEK293 lysate, transfected with scrambled or b-arrestin 2 siRNA, and probed with b-arrestin 2, PDE4D, PKAa-catalytic
subunit or AKAP79 antibodies (Supplementary data). (B) Average densitometry for b-arrestin 2, PDE4D3 and PKA. (C) Average densitometry
for AKAP79. Data are expressed as b-arrestin 2 siRNA band density relative to scrambled siRNA controls. Bars represent means, error bars
s.e.m. *Po0.05 and **Po0.01 versus scrambled siRNA control, one-way ANOVA with Newman–Keuls multiple comparison test.
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putative phosphorylation motif (700-RQRKSMDSK-708)
(Figure 10). Importantly, the stimulatory (AKAP79 and
AC2) and regulatory (b-arrestin 2, PDE4D3 and PKA) compo-
nents of the signalosome appear to interact with spatially
distinct areas of the RXFP1 C-terminus.
Figure 9 AKAP79 tethers AC2 to RXFP1 independently of the regulatory complex; b-arrestin 2 controls the association of RXFP1 with PDE4D3
and PKA. To examine the protein–protein interactions within the RXFP1 signalosome, the effect of knockdown of either AKAP79 or b-arrestin 2
upon AC2-HA IP and PDE4D3 DN IP was assessed (n¼3–4). (A) Representative blots of AC2-HA or PDE4D3 DN IP from lysate of cells co-
expressing AC2-HA and FLAG-RXFP1, and transfected with AKAP79 shRNA or b-arrestin 2 siRNA, and probed with FLAG, AKAP79, HA,
b-arrestin 2, PDE4D and PKAa-catalytic subunit antibodies (Supplementary data). (B) Average densitometry for AC2-HA IP. (C) Average
densitometry for PDE4D3 DN IP. Data are expressed as band density relative to control. Bars represent means, error bars s.e.m. *Po0.05,
**Po0.01 and ***Po0.001 versus control;
^Po0.05 and
^^Po0.01 versus b-arrestin 2 knockdown for AC2-HA IP or versus AKAP79
knockdown for PDE4D3 DN IP; one-way ANOVA with Newman–Keuls multiple comparison test.
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proposing is not only supported by various biochemical
strategies, but also that the complex is altered in a predictable
manner when individual components are knocked down. For
instance, b-arrestin 2 knockdown only prevents the associa-
tion of AC2 (in AC2 co-IP) with PDE4D3 and PKA, but
completely removes any protein interactions detected by
PDE4D3 co-IP; similarly, knockdown of AKAP79 only pre-
vents the association of PDE4D3 with AC2 (in PDE4D3 co-IP),
but completely removes any protein interactions detected
by AC2 co-IP. Thus, the consequences of targeted knockdown
are not reﬂective of proteins that merely directly interact,
but point to a deﬁned and inter-dependent complex organiza-
tion (Figure 10). Of even greater signiﬁcance is the fact that
the RXFP1 signalosome, as identiﬁed by these biochemical
strategies, shows the same functional dependency for its
composition; that is to say that perturbing individual compo-
nents has outcomes that are predicted based upon the
biochemical measurements. For instance, b-arrestin 2 knock-
down mimics PDE4D3 or PKA inhibition; similarly, the
knockdown of AKAP79 reﬂects inhibition of AC2, or indeed
Gas and Gbg. Finally, the experiments that effectively
involved structure-functional analysis of the requirements
of the receptor for participation in this complex are
particularly valuable. A construct with a Ser
704 mutation
pulled down only some (AKAP79 and AC2) but not all
components of the complex, and simultaneously exhibited
the anticipated functional outcomes. Furthermore, a chimeric
receptor (RXFP1/2) preserved only the familiar Gas-depen-
dent classical response and lost the novel signalling identiﬁed
here. Thus, we would propose that the complex we have
identiﬁed is clearly deﬁned and exists in both molecular and
functional terms.
The use of highly sensitive single-cell techniques has
revealed a cellular response to sub-picomolar concentrations
of relaxin, which provides for the ﬁrst time an important
physiological relevance for circulating levels of this pleiotro-
pic hormone. Furthermore, this approach has allowed the
identiﬁcation of a pre-assembled, ligand-independent and
constitutively active RXFP1 signalosome, with well-deﬁned
stimulatory and regulatory components (Figure 10). The
identiﬁcation of a distinct cellular response to low rather
than high concentrations of relaxin implies that investigators
have previously only been examining one component of the
relaxin effect. This new discovery provides opportunities for
additional research of the function of this distinct pathway in
the multiple physiological and pathological conditions regu-
lated by relaxin. Further, this ﬁnding could have major
ramiﬁcations for understanding the function of relaxin in
various physiological systems, and has even greater implica-
tions for the use of relaxin or relaxin derivatives as thera-
peutic agents in pathologies including heart failure and
cancer metastases. Finally, the sensitivity of this pre-
assembled signalosome to attomolar concentrations of ligand
represents a novel paradigm in GPCR signalling, and may
facilitate the identiﬁcation of similar responses in other
receptor systems.
Materials and methods
Peptides
Recombinant human relaxin was provided by Corthera, Inc. Human
INSL3 was synthesized by Professor John D Wade (Howard Florey
Institute, Australia).
Constructs
All RXFP receptor constructs (Halls et al, 2009), b-arrestin 1, b-
arrestin 2 and scrambled siRNA (Lynch et al, 2005; Willoughby
et al, 2007), AKAP79 shRNA and pSilencer (Hoshi et al, 2005;
Willoughby et al, 2007), dominant negative PDE4D3 and PDE4D5
(Baillie et al, 2003; McCahill et al, 2005), and Ad-glEpac1, glEpac2,
pmEpac2 and pmEpac2 R297E have been described previously
(Nikolaev et al, 2004, 2005; Mironov et al, 2009; Wachten et al,
2010). b-Arrestin 1, b-arrestin 2, scrambled siRNA and dominant
negative PDE4D3 and PDE4D5 were kindly provided by Professor
Miles D Houslay (University of Glasgow, UK); AKAP79 shRNA and
pSilencer were kindly provided by Professor John D Scott
(University of Seattle); Ad-glEpac1 and glEpac2 were kindly
provided by Professor Martin J Lohse (University of Wu ¨rzburg,
Germany).
GST-tagged fragments of the RXFP1 C-terminus were generated
by amplifying the required region from the full-length cDNA using
PCR, and cloning into pGEX-4T1. AC2-HA was generated by adding
a HA-tag to the C-terminus of rat AC2 by PCR, and cloned into
pcDNA3.0.
Cell culture
Cells were maintained as described in Supplementary data. Primary
rat cardiac ﬁbroblasts were prepared as described previously
(Woodcock et al, 2002). Transient transfections were performed
using Lipofectamine 2000 (Invitrogen). For siRNA, shRNA, pSilen-
cer and dominant negative PDE4D3 or PDE4D5, cells were
transfected with the relevant construct followed 24h later by
receptor and biosensor DNA (single-cell cAMP measurements) or
receptor and AC2-HA (co-IP studies). Adenoviral infection of rat
cardiac ﬁbroblasts used a multiplicity of infection of 200 PFU/well.
Single-cell cAMP measurements
Cells were seeded onto 18mm poly-L-lysine-coated coverslips 24h
following transfection, or 6h following adenoviral infection, in
0.5% (v/v) FBS-culture medium, and used the following day.
Fluorescent imaging was performed using an Andor Ixonþ CCD
camera and Optosplit (505DC) (Cairn Research) as described
Figure 10 A cartoon illustrating the components of the constitu-
tively assembled RXFP1 signalosome that can be activated by sub-
picomolar concentrations of relaxin. The interaction of AKAP79
with helix 8 of the RXFP1 C-terminus allows the co-localization of
the receptor with AC2. AC2 is stimulated by Gas and Gbg,t o
increase cAMP accumulation. This increase in cAMP results in
sequential activation of PKA and PDE4D3. b-Arrestin 2 interacting
with Ser
704 (indicated with an asterisk) of the receptor C-terminal
tail localizes the tonic opposition mediated by PKA and PDE4D3.
Importantly, the stimulatory (AKAP79 and AC2) and regulatory (b-
arrestin 2, PDE4D3 and PKA) components interact with distinctly
deﬁned regions of the C-terminal tail.
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software (Molecular Devices).
Data were analysed by expressing the change in CFP (470nm)
versus YFP (535nm) emission ratio relative to a maximal stimulus
(10mM forskolin, 100mM IBMX and 100nM PGE1). The area under
the curve (AUC) for the ﬁrst 5 or 12min (HeLa cells only) was
calculated using GraphPad Prism, and takes into account changes in
both the rate and magnitude of the cAMP response. The biphasic
concentration-dependent increase in cAMP in response to relaxin
was also evident when data were analysed by ‘peak-response’ or
‘rate of response’ (Supplementary Figure S1); as increasing
concentrations of relaxin amplify both the rate and magnitude of
the cAMP response, the AUC analyses allows incorporation of the
most information. There was no difference in the cAMP response to
relaxin or the associated effects of inhibitors over a longer time
course of 20min (Supplementary Figure S1). Biphasic concentra-
tion–response curves were ﬁt using a biphasic non-linear regression
analysis; classical concentration–response curves were ﬁt using
a log[agonist] versus response non-linear regression analysis
(GraphPad Prism).
GST pull-down assay
GST fragments of the RXFP1 C-terminus were expressed in BL21-
Rosetta cells at 301C following induction with 0.1mM isopropyl
b-D-1-thiogalactopyranoside (IPTG). Cells were lysed by sonication
in lysis buffer (10mM ethylenediaminetetraacetic acid (EDTA),
1mM phenylmethylsulphonyl ﬂuoride (PMSF), 1mM benzamidine,
protease inhibitors, 1mg DNase in phosphate-buffered saline (PBS))
supplemented with 200mg/ml lysozyme. Homogenates were
centrifuged (27000g,4 1C, 15min), supernatant passed through a
glutathione-Sepharose 4B resin, and washed until no protein
remained in the eluate. An equal volume of PBS (containing
0.02% NaN3) to resin was added to create a 50% slurry.
HEK293 cells were lysed in GST-Fish buffer (10% v/v glycerol,
100mM NaCl, 50mM Tris, pH 7.4, 0.5% Tween-20, 2mM
dithiothreitol, 1mM PMSF, 1mM benzamidine, protease inhibitors,
10 mM b-glycerophosphate, 2mM sodium orthovanadate) by
rotating for 30min at 41C, before centrifugation (12000g,4 1C,
15min). The cell lysate was incubated with GST beads for 4h at 41C
with rotation. GST beads were washed twice in GST-Fish buffer, and
bound proteins eluted in Laemmli buffer and boiled for 5min prior
to immunoblotting (Supplementary data).
HA-IP
HEK293 cells co-expressing pcDNA and AC2-HA, AC2-HA and
FLAG-RXFP1, or AC2-HA and FLAG-RXFP1 S704A were washed
with PBS and lysed in solubilization buffer (50mM Tris, pH 7.4,
150mM NaCl, 0.1mM EDTA, 0.3% (v/v) NP-40, 100mME G T A ,
protease inhibitors, 10mM b-glycerophosphate and 2mM sodium
orthovanadate) using a 21-gauge needle. The cell suspension
was centrifuged (900g,4 1C, 5min) before IP using anti-HA
afﬁnity-agarose beads (Roche). Lysate was rotated with 100mlp r e -
washed bead slurry (50%) for 4h at 41C. Beads were washed twice
with wash buffer (solubilization buffer with 0.03% (v/v) NP-40),
and proteins were eluted in wash buffer with 1% (w/v) SDS and
DNase. Laemmli buffer was added and samples incubated at 371C
for 30min prior to immunoblotting (Supplementary data).
PDE4D3-IP
HEK293 cells co-expressing dominant negative PDE4D3, and
pcDNA and AC2-HA, AC2-HA and FLAG-RXFP1, or AC2-HA and
FLAG-RXFP1 S704Awere washed with PBS and lysed in lysis buffer
(50mM Tris, pH 7.4, 1mM EDTA, 1mM MgCl2, 150mM NaCl, 0.5%
(v/v) Tween-20, protease inhibitors) using a 21-gauge needle. The
cell suspension was centrifuged (200g,4 1C, 3min) before IP using
rabbit anti-PDE4D antibody (1:150; Abcam). Samples were rotated
for 2h at 41C, protein G agarose (30ml of a 50% slurry) was added,
and samples rotated for 2h at 41C. Beads were washed twice with
wash buffer (lysis buffer with 0.05% (v/v) Tween-20), and bound
proteins eluted in Laemmli buffer with incubation at 371C for
30min prior to immunoblotting (Supplementary data).
Statistical analyses
Single-cell FRET data were analysed by two-way ANOVA with
Bonferroni post tests and densitometric analyses, by one-way
ANOVA with Newman–Keuls multiple comparison test (GraphPad
Prism). Data are expressed as mean±s.e.m of n cells/experiments,
with statistical signiﬁcance accepted at Po0.05.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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